A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Head and neck cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Roche
- 28 Jun 2018 Planned End Date changed from 11 Oct 2019 to 10 Sep 2020.
- 28 Jun 2018 Planned primary completion date changed from 14 Sep 2018 to 18 Jul 2019.
- 24 Jun 2018 Planned number of patients changed from 120 to 250.